This was supported by examining a tissue microarray of neuroblastoma patient samples where 64.3% of patients with MYCN amplification expressed moderate (2+) to high (3+) XIAP whereas the majority of non–MYCN-amplified patients had null (0) to low (1+) XIAP expression (Fig. 1B; Supplementary Data S1). This evidence concerns the gene MYCN and neuroblastoma.